• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Drug improves cystic fibrosis pulmonary inflammation and protein function [PreClinical]

byCorinne FoleyandJessica Lau
June 18, 2017
in Chronic Disease, Preclinical, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Thymosin α1 (Tα1), an immunomodulatory drug currently in use, decreased lung inflammation in a mouse model of cystic fibrosis (CF).

2. In mice, administration of Tα1 improved the localization and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Evidence Rating Level: 1 (Excellent)

Study Rundown: CF is a disorder caused by mutations in the gene that encodes the CFTR protein, leading to chronic pulmonary infections as well as other complications. Therapies for this condition involve improving the function of the mutated CFTR and using immunomodulatory therapies to suppress the hyperinflammatory response of these patients. This study investigated the potential for Tα1 (Zadaxin), an immunomodulatory drug currently used to treat viral infections and other conditions, to address both of these aspects of treating CF.

In a mouse model of CF, the administration of Tα1 led to a decrease in pro-inflammatory markers and an increase in anti-inflammatory markers. In CF cells and mice, treatment with Tα1 increased CFTR expression at the plasma membrane through reducing endosomal targeting. This increase in cell surface expression was accompanied by an increase in activity of the protein, demonstrating potential pulmonary function improvement following treatment with Tα1.

This study elucidated a promising candidate therapy for CF. By simultaneously addressing the need to improve CFTR activity and reduce inflammation in CF, this drug demonstrated potential as a single-molecule CF therapy. In addition, since this drug is already currently on the market and is known to be safe, future clinical trials can focus on testing its efficacy in patients with CF.

Click here to read the study Nature Medicine

RELATED REPORTS

Urine bicarbonate excretion associated with cystic fibrosis transmembrane conductance regulator function

Newborn screening for cystic fibrosis improves nutritional outcomes

Higher body mass index associated with improved cystic fibrosis-related clinical outcomes

Relevant Reading: New and emerging targeted therapies for cystic fibrosis

In-Depth [animal study]: An airway epithelial cell line expressing p.Phe508del-CFTR, the most common mutation seen in patients with CF, was treated with Tα1. There was an increase in expression of IDO1, a protein involved in immune tolerance and known to be defective in CF patients. Next, Tα1 was administered to mice with the p.Phe508del-CFTR mutation that were infected with Aspergillus fumigatus to establish chronic lung disease. Treatment led to a decrease in lung pathology, fungal growth (p<0.0001), and neutrophil infiltration (p<0.0001). In addition, levels of pro-inflammatory cytokines such as TNF-α and IL-17A were decreased while levels of anti-inflammatory cytokines such as IL-10 were increased (p<0.01).

Next, the effect of Tα1 on CFTR function was evaluated. After treating p.Phe508del-CFTR airway epithelial cells with Tα1, western blotting demonstrated an increase in the plasma membrane localization of CFTR (p<0.001). CTFR was found to colocalize with Rab9, a marker of recycling endosomes, indicating that Tα1 improved CTFR function by decreasing breakdown and inducing proper folding. Tα1 also increased the half-life of the mutant CFTR through the reduction of ubiquitination, as demonstrated by immunoprecipitation and western blotting (p<0.05).

In p.Phe508del-CFTR mice treated for 6 days with Tα1, histology showed increased plasma membrane localization of CFTR. The function of the mutated CFTR was assessed through measuring chloride ion conductance using patch-clamp experiments following forskolin and genistein stimulation. Tα1 restored channel activity and gating in the lung epithelial cells of these mice, leading to a two-fold increase in open probability.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: cystic fibrosis
Previous Post

Low-cost biochip isolates cells for clinical diagnosis [PreClinical]

Next Post

Pediatric firearm injuries substantial cause of premature death, disability

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Chronic Disease

Urine bicarbonate excretion associated with cystic fibrosis transmembrane conductance regulator function

November 17, 2022
Nebulized saline not associated with bronchiolitis hospital length of stay
Chronic Disease

Newborn screening for cystic fibrosis improves nutritional outcomes

August 18, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Chronic Disease

Higher body mass index associated with improved cystic fibrosis-related clinical outcomes

March 7, 2022
Higher sodium intake linked to more aggressive multiple sclerosis
Chronic Disease

Sweat chloride levels predict future cystic fibrosis diagnosis in those with inconclusive diagnosis at birth

November 17, 2021
Next Post
AAP supports mindfulness of children’s media consumption

Pediatric firearm injuries substantial cause of premature death, disability

Study reveals suburban clinicians’ perspectives on screening for food insecurity

Study reveals suburban clinicians’ perspectives on screening for food insecurity

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The SHIFT: Ivabradine in congestive heart failure [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Factors associated with breastfeeding rates in Canada
  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options